Geron’s Corporate History

2013

  • Presented preliminary clinical data from the investigator-sponsored trial of imetelstat in myelofibrosis (MF) at the American Society of Hematology (ASH) annual meeting
  • Presented updated clinical results from Phase 2 proof-of-concept trial of imetelstat in essential thrombocythemia (ET) at the European Hematology Association (EHA) congress
  • Focused clinical development of imetelstat on hematologic myeloid malignancies, based on proof-of-concept data in essential thrombocythemia (ET) and progress of investigator-sponsored trial in myelofibrosis (MF)

2012

  • Presented positive proof-of-concept data from Phase 2 clinical trial of imetelstat in patients with essential thrombocythemia (ET) at the American Society of Hematology (ASH) annual meeting
  • Initiated investigator-sponsored trial of imetelstat in patients with myelofibrosis (MF)
  • Discontinued development of GRN1005; asset returned to Angiochem, Inc.
  • Discontinued Phase 2 clinical trial of imetelstat in patients with metastatic breast cancer
  • Completed enrollment in Phase 2 clinical trial of imetelstat in patients with advanced non-small cell lung cancer
  • Completed enrollment in Phase 2 clinical trial of imetelstat in patients with metastatic breast cancer

2011

  • Initiated Phase 2 clinical trial of GRN1005 in patients with brain metastases arising from lung cancer (Study GRABM-L; GRN1005 Against Brain Metastases - Lung Cancer)
  • Initiated Phase 2 clinical trial of GRN1005 in patients with brain metastases arising from breast cancer (Study GRABM-B; GRN1005 Against Brain Metastases - Breast Cancer)
  • Presented final data from the Phase 1 clinical trials of GRN1005 in patients with brain metastases from solid tumors and primary brain cancer at AACR-NCI- EORTC International Conference
  • TA Therapeutics, the joint venture in Hong Kong to research and develop telomerase activators, was consolidated into Geron

2010

  • In-licensed GRN1005 and peptide technology from Angiochem, Inc. to facilitate transfer of anti-cancer compounds, specifically tubulin disassembly inhibitors, across the blood-brain barrier for the treatment of primary brain cancers and cancers that have metastasized to the brain
  • Presented final data from the Phase 2 clinical trial of GRNVAC1 at the ASH annual meeting showing that vaccination is associated with prolonged disease-free survival in selected patients with high-risk AML
  • Publications in Cancer Research and PLoS ONE demonstrating that imetelstat targets cancer stem cells from multiple myeloma, pancreatic and breast cancers
    Read Cancer Research Publication
    Read PLoS ONE Publication
  • Initiated Phase 2 clinical trial program for imetelstat

2009

  • Nobel prize in Physiology or Medicine awarded to former Geron collaborators, Elizabeth H. Blackburn and Carol W. Greider, along with Jack W. Szostak for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase

2008

  • Combined licensing and operating companies for animal cloning technologies by merging stART Licensing, Inc., a joint venture with Exeter Life Sciences, and ViaGen, Inc., a subsidiary of Exeter Life Sciences

2007

  • Initiated Phase 2 clinical trial of the telomerase cancer vaccine, GRNVAC1, in patients with acute myelogenous leukemia in complete remission

2006

  • Data showing imetelstat is active against cancer stem cells from multiple myeloma patients presented at the ASH annual meeting

2005

  • Initiated collaboration with Merck to develop cancer vaccines targeting telomerase
  • Initiated first Phase 1 clinical trial of imetelstat (GRN163L)
  • Formed stART Licensing, Inc., a joint venture with Exeter Life Sciences, to manage and license a broad portfolio of intellectual property rights related to animal reproductive technologies
  • Publication in Journal of Immunology of final results from Phase 1/2 clinical trial of telomerase cancer vaccine in patients with metastatic prostate cancer showing that the vaccination protocol successfully generated telomerase-specific T-cell responses, the vaccine was well tolerated with no major treatment-related toxicities and vaccination was associated with a significant increase in PSA doubling time and clearance of circulating tumor cells
    Read Publication
  • Formed TA Therapeutics Ltd., a joint venture in Hong Kong to research and develop telomerase activator drugs

2004

  • Publication in Journal of Immunology on the use of telomerase activation to increase the lifespan and augment the antiviral activities of HIV-1 specific immune cells
    Read Publication
  • Acquired exclusive license rights from Argos Therapeutics (formerly Merix Bioscience) for dendritic cell-based therapeutic cancer vaccines using telomerase as an antigen

2003

  • Preliminary results from Phase 1 clinical trial of dendritic cell-based telomerase immunotherapy in metastatic prostate cancer showed vaccinations were very well tolerated, without any adverse effects attributable to the treatment, and that vaccination resulted in the generation of an anti-telomerase immune response in almost all patients - the data were presented via webcast instead of the AACR meeting, which was cancelled due to SARS
  • Publication in Cancer Gene Therapy showing that different types of cancer cells can be killed by telomerase-based immunotherapy
    Read Publication
  • Publication in Oncogene showing synergy of telomerase inhibition with radiotherapy and many current cancer chemotherapy agents
    Read Publication

2002

  • Acquired phosphoramidate chemistry IP estate from Lynx Therapeutics

2001

  • Publication in Cancer Research demonstrating that blocking telomerase production in breast cancer cells leads to increased sensitivity to the widely used breast cancer chemotherapeutic agent
    Read Publication
  • Publication in Gene Therapy demonstrating the utility of the human telomerase promoter to drive the preferential expression of therapeutic genes in cancer cells
    Read Publication

2000

  • Publication in Nature Medicine demonstrating the use of telomerase as an antigen to stimulate an immune response that inhibits tumor growth in animals and kills human tumor cells in vitro
    Read Publication

1999

  • Acquired Roslin Bio-Med and nuclear transfer technology
  • Publication in Nature Genetics demonstrating that telomerase expression in normal cells confers an infinite replicative capacity, but does not result in cellular changes associated with cancer
    Read Publication

1998

  • Publication in Science showing that telomerase can increase the replicative lifespan of cells
    Read Publication

1997

  • Publication in Science reporting cloning of the gene for the human telomerase catalytic protein
    Read Publication
  • Telomerase inhibition collaboration signed with Pharmacia & Upjohn for Europe and continued screening for small molecule TI drug

1996

  • Geron IPO

1995

  • Series D financing closed
  • Telomerase inhibition collaboration signed with Kyowa Hakko for Asia. Screening for small molecule TI drug.
  • Publication in Science reporting cloning of human telomerase RNA (hTR)
    Read Publication

1994

  • Publication in Science showing telomerase is active in many different kinds of cancers and cancer cell lines, but is not found in normal tissues
    Read Publication
  • Series C financing closed

1993

  • Series B financing closed

1992

  • Series A financing closed

1990

  • Incorporated in the State of Delaware
Close
Form content here please :)